We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Glycated Albumin Levels in Tears Allow Noninvasive Glucose Testing

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Image: Glycated albumin levels in tears allows for noninvasive glucose testing (Photo courtesy of The University of Melbourne).
Image: Glycated albumin levels in tears allows for noninvasive glucose testing (Photo courtesy of The University of Melbourne).
The glucose test helps determine if a person’s glucose level is too high or too low, which can indicate the presence of Type 2 diabetes and other medical conditions. The two most common types of glucose testing are the fasting plasma glucose test and the random plasma glucose test.

Glycated albumin is albumin that has been glycated (bound to sugar). Albumin is the most common type of protein found in blood (~80% of circulating proteins) and is replaced in the body about every 20-25 days. Excessive glycation of albumin causes irreversible damage to organs and their vasculature.

Scientists at the University of Tokyo (Tokyo, Japan) recruited 100 adults (mean age, 50.87 years; 71% men) with diabetes from outpatient and inpatient practices. Participants had tear samples collected at the same time as a blood sampling tests. The team measured glycated albumin levels in tears with liquid chromatography-mass spectrometry, whereas blood sample levels were measured through an enzymatic method.

The investigators reported that glycated albumin levels were appropriately measured in 99 of 100 participants. Initial results showed a correlation between glycated albumin levels in blood and those measured in tears (beta = 0.722; 95% CI, 0.585-0.859). The correlation between tear levels and blood levels remained after adjustments for age, sex, nephropathy stage and obesity (beta = 0.738; 95% CI, 0.594-0.882). HbA1c was not assessed in the study.

Masakazu Aihara, MD, PhD, a project research associate and lead author of the study, said, “To achieve strict glucose control preventing diabetic complications, many patients take HbA1c tests in hospitals and some take self-monitoring of blood glucose. Continuous glucose monitoring has also been put into practical use, but all of these measurement methods are invasive, and it is a burden on the patients. We focus on tears, which can be collected with noninvasive ways, and found that the glycated albumin levels in tears and blood had strong correlation. Since glycated albumin reflects two week average blood glucose levels, it does not need to be measured as frequently as self-monitoring and can be used in the same way as HbA1c tests.”

Dr. Aihara added “The correlation of glycated albumin levels in tears and blood that we found in this study was much stronger than that of glucose levels, and a measurement method of tear glycated albumin can be used in clinical practice.” The study was presented at the European Association for the Study of Diabetes virtual meeting, held 21-25 September, 2020.

Related Links:
University of Tokyo

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.